Hello everyone. Good morning. It's a pleasure to be here today. Um, and I'm happy to speak with you about precision cardiovascular or PCV. Uh, we are developing uh a pulmonary artery pressure monitoring system for heart failure patients. So the funny situation uh in heart failure today is that there is a way to manage patients who are out of hospital. It's proven to work. It's proven to be effective. However, adoption is well below where it should be. Um, if you think of pacemakers where perhaps nine out of 10 indicated patients would be uh eligible and and receive it, it's well under one in 10 in the case of PA pressure monitoring. So, we all agree that that's an issue. The issues arise in friction points initially when clinicians speak with their patients, the patients journey and also in terms of nursing interpretation. Now what we um well the these are some of the issues that arise. Uh you'll find that many patients uh the data that comes out of there they themselves are not engaged engaged in um the clinicians are unable to determine without context how to uh manage the patients and ultimately for the caregivers for the family members there's a burden and and a stress that is quite high. We're not the first to look at this. In fact, there are two commercial stage companies involved in this space. However, um neither of those companies actually address uh some of the issues we've uh spoken of earlier. But what we have done is that we've taken proven regulatory pathways and reimbursement which is nationwide in the US. Uh but our underlying technology is different. surface acoustic wave coming from the world of automotive is much lower power and our chosen manufacturing technique on monoristine quartz is resilient to uh motion to uh ambulatory uh noise. So as a result a patient can be going upstairs guarding on all fours uh sleeping and all the time we're able to measure. Uh so this is what we mean by context it's what we mean by roundthe-clock measurement which is absent today. Uh there's also the case of stability. So over time over 5 years a lot of these sensors drift that's not a characteristic of our chosen technology and implementation. So uh the system is made up of uh three architectural components. Uh the key one is the uh implanted lifelong sensor which is passive. Um so that is in our case already designed frozen and stable. uh where we are uh very visibly different from our peers is the second part that uh tracker patch which we call a reader. So this is battery powered in our case as opposed to mains electricity for others. uh this means that it can be used anywhere any time and it gives rise to the possibility for passive measurement without the patient being involved and thereafter there are cloud analytics in order to determine um by a facilitator triage uh for the nurses to quickly act on actionable data our team is here so uh I'm Muhammad the CEO I come from a background of venture consumer electronics and medtech I'm joined by Matthew Mace our independent director who's ex Abbott and St. Jude and exacerai and has a wealth of expertise as a clinical physiologist. Uh Matt Grimdale is our CFO. We have a legacy of strong research going back uh over 20 years as well as Professor Sir Magda who's famous on both sides of the Atlantic for cardiac transplants and then a growing team in data science and uh development as well as a strong in-house regulatory and quality team. Um on the right our partners we have uh worldclass foundaries um and clinical partners as well as notable uh CDMO support as we go on our journey and service design support. This is what we're uh undertaking now. So um what you see here this pig this is the first time anyone has done this taking PA pressure measurements in a moving uh animal model. So uh never before have you had a moving pig go up an incline for example and have its pressure measured at the same time as its activity. Um and this is what can arise from it. So in understanding if any deterioration in the heart condition um and pressures of the pig is appearing at resting state or in an active mode differenting differentiating between the two and understanding context and taking that to a human model thereafter. The learnings from here which is our gen one system are being applied as we speak to our uh v2 design as we call it. So this is our gen two reader which is uh under design and due to finalize uh early next year. Uh and this takes on board a lot of the uh proven technology and validated approaches in a very low power design that is passive and easy for the patient to use. As mentioned uh the the area of heart failure management remotely is one where uh there are the patients very very poor penetration clinical workflow is in our view highly flawed today. Uh there's also a difficulty of patients engaging in everyday activities uh and and not needing to do anything. So so that's a gap there and there are no such portable systems as ours in the market today. So you can't really travel. So it's a case of wide space and making implementation and ease better rather than needing to prove anything in terms of clinical Um these are all the implants available today for um management of heart failure. Um for those uh who are following Victorious has just been acquired by Edward so that needs to be uh updated. Um so the main point here is that all these devices require the patient to do something from his or her home. We're the only ones who have a ubiquitous unobtrusive offering so that anytime anywhere as the clinician and patient need readings can be taken in the background. This is the future of heart failure management passive monitoring where the patient forgets about it and the readings are taken in the background. So we have uh a legacy as mentioned and uh patents developed and uh uh an existing uh quality and grant support system and acute tests. Uh but our upcoming milestones consist of a publication uh later this year in terms of the ambulatory uh uh animal model. Uh we have also uh on ongoing user needs validation. So we're benefiting from the fact that our peers are in the market today and can learn directly from clinicians as to why many of them are adopting or importantly not. Uh thereafter we have a discussion with the FDA on our clinical trial design notably the pivotal which will come up later and ongoing service uh model validation. Uh so some of the milestones are shown here. So uh the publication later this year clinical feedback in a Q sub a design freeze of the overall V2 system that will go into our EFS later on. Uh we're engaging CDMOS at both subsystem and full system level. Uh we have our GLP study in the second half of next year aiming for an international EFS in the UK and the US uh as of the beginning of 27 which is shown here. So uh over the course of 27 we have uh straddling uh US and UK sites. Then there's the pivotal study which we envisionage actually will most likely be uh a single arm given uh our predecessors in the marketplace. Um and this shows some of our timeline uh forecasted ahead. Ultimately, there's a viewpoint that as the patient forgets about the implant, as it becomes more passive, really the future of heart failure management is one where you have more of this gold standard data to interpret and to integrate with other biomarkers that are non-invasive. There's a lot of talk of techmed and medtech and the future and intersection and why it hasn't happened. But really we believe that this can only happen if there's uh an ability to present some of this clinically validated data unobtrusively passively easily to clinicians and to partners in order to assimilate that and attribute changes to non-invasive biomarkers. So uh we believe that there's a strong future with uh technology partners outside of medtech as long as this happens and the approach is uh is one that we're taking here. [sighs] So, we've raised to date privately through a mix of commercial uh uh and ground sources uh over $5 million. We have an upcoming fund raise to service our first clinical studies commencing uh from November of 15 million and a future fund raise to service our pivotal study. Looking forward to engaging with uh with investors here and also um I'm joined by Matthew Mace uh thereafter. So, I'm happy to take your questions with him. Thank you very much. It's a pleasure to speak with you. Thank you.